Vaxcyte officer plans sale of about $1.15M in shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vaxcyte, Inc. officer Harpreet S. Dhaliwal reported a planned sale of 17,000 common shares, with an approximate market value of $1,153,101.50 and an approximate sale date of November 11, 2026. Dhaliwal acquired 17,000 common shares through an exercise of stock options on November 11, 2026, with cash payment.
Dhaliwal also reported a sale during the prior three months of 17,000 common shares on August 5, 2026, for gross proceeds of $935,066.15. The reported Rule 10b5-1 plan adoption or instruction date is April 6, 2026.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Aggregate Market Value financial
Exercise of Stock Options financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.